BRAF-mutations in non-small cell lung cancer

被引：63
|
作者：
Brustugun, Odd Terje [1 ,2 ]
Khattak, Asma Malik [3 ]
Tromborg, Anette Kjoshagen [3 ]
Beigi, Marzieh [3 ]
Beiske, Klaus [3 ]
Lund-Iversen, Marius [3 ]
Helland, Aslaug [1 ,2 ]
机构：
[1] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, N-0310 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, N-0310 Oslo, Norway
来源：
LUNG CANCER | 2014年 / 84卷 / 01期
关键词：
EGFR-mutation; BRAF-mutation; Genetic testing; Lung cancer; Tyrosine kinase inhibitors; ADENOCARCINOMAS; FEATURES; PATIENT;
D O I：
10.1016/j.lungcan.2014.01.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objectives: Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. Material and methods: NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. Results: We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 23% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). Conclusion: BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：36 / 38
页数：3
相关论文
共 50 条
  • [41] EGFR mutations in non-small cell lung cancer - Clinical implications
    Charpidou, Andriani
    Blatza, Despoina
    Anagnostou, Elsa
    Syrigos, Konstantinos N.
    IN VIVO, 2008, 22 (04): : 529 - 536
  • [42] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Leah Wells
    Angel Qin
    Current Treatment Options in Oncology, 2023, 24 : 1802 - 1814
  • [43] Immunotherapy in non-small cell lung cancer harbouring driver mutations
    Addeo, Alfredo
    Passaro, Antonio
    Malapelle, Umberto
    Banna, Giuseppe Luigi
    Subbiah, Vivek
    Friedlaender, Alex
    CANCER TREATMENT REVIEWS, 2021, 96
  • [44] Racial Diversity of Actionable Mutations in Non-Small Cell Lung Cancer
    Bollig-Fischer, Aliccia
    Chen, Wei
    Gadgeel, Shirish M.
    Wenzlaff, Angela S.
    Cote, Michele L.
    Schwartz, Ann G.
    Bepler, Gerold
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 250 - 255
  • [45] Non-small cell lung cancer - mutations, targeted and combination therapy
    Kutkowska, Justyna
    Porebska, Irena
    Rapak, Andrzej
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2017, 71 : 431 - 445
  • [46] HER-2 Mutations in Non-Small Cell Lung Cancer
    Sen, Erdem
    Yavas, Guler
    Ata, Ozlem
    MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (03) : 322 - 325
  • [47] Uncommon EGFR mutations in advanced non-small cell lung cancer
    O'Kane, Grainne M.
    Bradbury, Penelope A.
    Feld, Ronald
    Leighl, Natasha B.
    Liu, Geoffrey
    Pisters, Katherine -M.
    Kamel-Reid, Suzanne
    Tsao, Ming S.
    Shepherd, Frances A.
    LUNG CANCER, 2017, 109 : 137 - 144
  • [48] Evaluation of genetic mutations in non-small cell lung cancer patients
    Rothstein, Miles
    Broughton, Phillip
    Markalunas, Ella
    Funkhouser, Avery
    Allen, Lorie
    Martin, Julie
    Edenfield, W. Jeffery
    Blenda, Anna V.
    CANCER RESEARCH, 2024, 84 (06)
  • [49] Non-small cell lung cancer with double driver mutations.
    Osoegawa, Atsushi
    Toyokawa, Gouji
    Ohba, Taro
    Miyawaki, Michiyo
    Yamaguchi, Masafumi
    Taguchi, Kenichi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    Sugio, Kenji
    CLINICAL CANCER RESEARCH, 2014, 20
  • [50] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Wells, Leah
    Qin, Angel
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1978 - 1993
12345